Vikas Dudeja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vikas Dudeja has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ashok K. Saluja
Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, Minnesota
2 shared publications Kaustav Majumder
Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA
2 shared publicationsRohit Chugh
Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA
2 shared publications- Selwyn Maurice Vickers
University of Alabama at Birmingham, Birmingham, AL
2 shared publications Sulagna Banerjee
Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA
2 shared publications- Sulagna Banerjee
Department of Surgery, University of Minnesota, Minneapolis, Minnesota
2 shared publications
Latest Publications
- 1 January 2016
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 20 (1) , 53-65
A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies
- 1 January 2016
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 20 (1) , 53-65
A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies
- Open Access
- 20 April 2015
- Published by Elsevier in Laboratory Investigation
- Vol. 95 (6) , 648-659
Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F
- 20 April 2015
- Published by Elsevier in Laboratory Investigation
- Vol. 95 (6) , 648-659
Open AccessTriptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F
- 1 June 2014
- Published by Elsevier in Cancer Letters
- Vol. 348 (1-2) , 156-166
Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the Death Receptor pathway
- 1 June 2014
- Published by Elsevier in Cancer Letters
- Vol. 348 (1-2) , 156-166
Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the Death Receptor pathway
- Open Access
- 11 September 2013
- Published by Springer Nature in Molecular Cancer
- Vol. 12 (1) , 105
miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death
Background: Pancreatic cancer is one of the most lethal human malignancies, with an all-stage 5-year survival of in vitro and in vivo, in killing pancreatic cancer cells. Decrease of Mcl-1 levels, either by siRNA or by treatment with triptolide results in cell death. Using pancreatic cancer cell lines, we have shown that miR-204, a putative regulator of Mcl-1, is repressed in cancer cell lines compared to normal cells. Over-expression of miR-204, either by a miR-204 mimic, or by triptolide treatment results in a decrease in Mcl-1 levels, and a subsequent decrease in cell viability. Using luciferase reporter assays, we confirmed the ability of miR-204 to down-regulate Mcl-1 by directly binding to the Mcl-1 3’ UTR. Using human xenograft samples treated with Minnelide, a water soluble variant of triptolide, we have shown that miR-204 is up-regulated and Mcl-1 is down-regulated in treated vs. control tumors. Conclusion: Triptolide mediated miR-204 increase causes pancreatic cancer cell death via loss of Mcl-1.
- 11 September 2013
- Published by Springer Nature in Molecular Cancer
- Vol. 12 (1) , 105
Open AccessmiR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death
Background: Pancreatic cancer is one of the most lethal human malignancies, with an all-stage 5-year survival of in vitro and in vivo, in killing pancreatic cancer cells. Decrease of Mcl-1 levels, either by siRNA or by treatment with triptolide results in cell death. Using pancreatic cancer cell lines, we have shown that miR-204, a putative regulator of Mcl-1, is repressed in cancer cell lines compared to normal cells. Over-expression of miR-204, either by a miR-204 mimic, or by triptolide treatment results in a decrease in Mcl-1 levels, and a subsequent decrease in cell viability. Using luciferase reporter assays, we confirmed the ability of miR-204 to down-regulate Mcl-1 by directly binding to the Mcl-1 3’ UTR. Using human xenograft samples treated with Minnelide, a water soluble variant of triptolide, we have shown that miR-204 is up-regulated and Mcl-1 is down-regulated in treated vs. control tumors. Conclusion: Triptolide mediated miR-204 increase causes pancreatic cancer cell death via loss of Mcl-1.